"No Big Deal": A Qualitative Study of Pharmacists' Perspectives on Dispensing Mifepristone for Medication Abortion
- PMID: 35918240
- DOI: 10.1016/j.whi.2022.06.007
"No Big Deal": A Qualitative Study of Pharmacists' Perspectives on Dispensing Mifepristone for Medication Abortion
Abstract
Introduction: Until December 2021, the United States Food and Drug Administration impeded abortion access by restricting pharmacists from dispensing mifepristone, one of two drugs used in medication abortion. This study aimed to explore pharmacists' perspectives on dispensing mifepristone.
Methods: We conducted semistructured interviews with pharmacists before and after participating in a pilot project where mifepristone was dispensed from their pharmacies. We thematically coded all interview transcripts, then summarized emergent themes related to pharmacists' support, comfort, experiences, and concerns around dispensing mifepristone.
Results: Between May 2018 and July 2020, we interviewed 29 pharmacists (22 at baseline and 15 at follow-up, with 8 completing both interviews) from 5 pharmacies. At both baseline and follow-up, interviewees strongly supported pharmacists dispensing mifepristone, feeling it would improve quality of care by providing more convenient medication abortion access and streamlined service delivery and take advantage of pharmacists' expertise and availability. All pharmacists interviewed at follow-up reported dispensing mifepristone except two who were willing but did not have the opportunity. Pharmacists experienced few challenges dispensing mifepristone. Their main concern was perceived discomfort that other pharmacists and pharmacy staff may experience, particularly in conservative areas or small pharmacies where pharmacists' refusal to dispense mifepristone could impede abortion access.
Conclusions: Most pharmacists supported dispensing mifepristone and were comfortable doing so after education on mifepristone and medication abortion. They dispensed mifepristone without difficulty, in a similar process as dispensing other medications. With the recent removal of U.S. Food and Drug Administration restrictions prohibiting it, our findings support the feasibility of pharmacists dispensing mifepristone.
Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.
Similar articles
-
Pharmacists' knowledge, perspectives, and experiences with mifepristone dispensing for medication abortion.J Am Pharm Assoc (2003). 2021 Nov-Dec;61(6):785-794.e1. doi: 10.1016/j.japh.2021.06.017. Epub 2021 Jun 18. J Am Pharm Assoc (2003). 2021. PMID: 34281806
-
Pharmacists' experiences dispensing misoprostol and readiness to dispense mifepristone.J Am Pharm Assoc (2003). 2024 Jan-Feb;64(1):245-252.e1. doi: 10.1016/j.japh.2023.10.030. Epub 2023 Oct 31. J Am Pharm Assoc (2003). 2024. PMID: 37913990
-
Dispensing mifepristone for medical abortion in Canada: Pharmacists' experiences of the first year.Can Pharm J (Ott). 2023 Jun 8;156(4):204-214. doi: 10.1177/17151635231176270. eCollection 2023 Jul-Aug. Can Pharm J (Ott). 2023. PMID: 37435503 Free PMC article.
-
Rural and small metro area naloxone-dispensing pharmacists' attitudes, experiences, and support for a frontline public health pharmacy role to increase naloxone uptake in New York State, 2019.J Subst Abuse Treat. 2021 Oct;129:108372. doi: 10.1016/j.jsat.2021.108372. Epub 2021 Mar 27. J Subst Abuse Treat. 2021. PMID: 34080543 Free PMC article. Review.
-
Evolving Global Perspectives of Pharmacists: Dispensing Medical Cannabis.Cannabis Cannabinoid Res. 2022 Apr;7(2):126-134. doi: 10.1089/can.2020.0144. Epub 2021 Apr 16. Cannabis Cannabinoid Res. 2022. PMID: 33998897 Free PMC article. Review.
Cited by
-
Willingness of Pharmacists to Prescribe Medication Abortion in California.JAMA Netw Open. 2024 Apr 1;7(4):e246018. doi: 10.1001/jamanetworkopen.2024.6018. JAMA Netw Open. 2024. PMID: 38598235 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical